|
|
Construction, Analysis and Characterization of Combinvssatorial Chimeric Antigen Receptor |
LIN Hai-ying**(),YAO Bin-yan,YU Yi-jie,YANG Yang |
Medicine Biotechnology and Engineering Research Institute,College of Biological Science and Technology, Fuzhou University,Fuzhou 350108,China |
|
|
Abstract Objective: To construct T cells encoding chimeric antigen receptor (CAR) targeting glypican-3 (GPC3) and chimeric antigen costimulatory receptor (CCR) targeting epithelial cell adhesion molecule (EPCAM), and analyze their activities in vitro. Methods: Gene fragments encoding EPCAM-CCR and GPC3-CAR was cloned into lentivirus vector plasmid. The recombinant CCR+CAR pCDH vector was identified by enzyme digestion, PCR and sequencing. T lymphocytes were isolated, activated and expanded. A stable combinatorial CAR modified cell line was generated using the lentivirus. Western blot, RT-PCR and flow cytometry (FCM) were used to verify the expression of CCR+CAR in CCR+CAR T cells. The secretion of cytokines IL-2, IL-4 and INF-γ was detected by ELISA. Results: The CCR+CAR pCDH lentiviral recombinant plasmid was successfully constructed. Human T lymphocytes were successfully isolated, activated and expanded. Human T lymphocytes were successfully infected with CCR+CAR pCDH lentivirus. RT-PCR and Western blot showed that the target protein was successfully expressed, and FCM analysis showed that the expression rate of CCR+CAR on CCR+CAR T cells was about 42%. ELISA was used to detect CCR+CAR co-culture with HepG2 and Lu-7 expressing GPC3 and EPCAM, the secretion levels of IL-2, INF-γ and IL-4 were higher, and the co-culture of human normal liver cells L-02 did not find effective activation of CCR+CAR T cells. Conclusions: The combined CCR+CAR T cells were successfully obtained, and the immune effect of CAR T combined with the two antigen recognition signals was attempted in hepatocellular carcinoma cells. The result laid a foundation for the immune effects in the subsequent in vitro experiments, and provided a potentially novel approach to augment the off-target effect of CAR-T immunotherapy for solid tumors.
|
Received: 01 December 2022
Published: 04 July 2023
|
|
|
|
[1] |
Ramos C A, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opinion on Biological Therapy, 2011, 11(7): 855-873.
doi: 10.1517/14712598.2011.573476
|
|
|
[2] |
Deepak R, Maria N, Irene G, et al. CEACAM7 is an effective target for CAR T-cell therapy of pancreatic ductal adenocarcinoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2021, 27(5): 1538-1552.
doi: 10.1158/1078-0432.CCR-19-2163
|
|
|
[3] |
Vitanza N A, Johnson A J, Wilson A L, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nature Medicine, 2021, 27(9): 1544-1552.
doi: 10.1038/s41591-021-01404-8
pmid: 34253928
|
|
|
[4] |
Majzner R G, Ramakrishna S, Yeom K W, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 2022, 603(7903): 934-941.
doi: 10.1038/s41586-022-04489-4
|
|
|
[5] |
Guo Y L, Feng K, Liu Y, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clinical Cancer Research, 2017, 24: 1277-1286.
doi: 10.1158/1078-0432.CCR-17-0432
|
|
|
[6] |
Shi D, Shi Y, Kaseb A O, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res, 2020, 26(15):3979-3989.
doi: 10.1158/1078-0432.CCR-19-3259
pmid: 32371538
|
|
|
[7] |
Kowolik C M, Topp M S, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research, 2006, 66(22): 10995-11004.
doi: 10.1158/0008-5472.CAN-06-0160
|
|
|
[8] |
Wilkie S, van Schalkwyk M C I, Hobbs S, et al. Dual targeting of ErbB2 and MUC 1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. Journal of Clinical Immunology, 2012, 32(5): 1059-1070.
doi: 10.1007/s10875-012-9689-9
pmid: 22526592
|
|
|
[9] |
郑乃溶, 徐建青. CAR-T细胞免疫疗法的研究进展. 复旦学报(医学版), 2022, 49(2): 295-299.
|
|
|
[9] |
Zheng N R, Xu J Q. Research progress of CAR-T cell immunotherapy. Fudan University Journal of Medical Sciences, 2022, 49(2): 295-299.
|
|
|
[10] |
Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol, 2016, 7: 690.
doi: 10.3389/fimmu.2016.00690
pmid: 28123387
|
|
|
[11] |
Jindal V, Arora E, Gupta S. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Medical Oncology, 2018, 35(6): 87.
doi: 10.1007/s12032-018-1149-9
pmid: 29730801
|
|
|
[12] |
Yu S N, Li A P, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology & Oncology, 2017, 10(1): 1-13.
|
|
|
[13] |
Kloss C C, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 2013, 31(1): 71-75.
doi: 10.1038/nbt.2459
pmid: 23242161
|
|
|
[14] |
Llovet J M, Chen Y B, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology, 2006, 131(6): 1758-1767.
doi: 10.1053/j.gastro.2006.09.014
pmid: 17087938
|
|
|
[15] |
Zhu Z W. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48(4): 558-564.
doi: 10.1136/gut.48.4.558
pmid: 11247902
|
|
|
[16] |
Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4, 387 tissue samples. American Journal of Clinical Pathology, 2008, 129(6): 899-906.
doi: 10.1309/HCQWPWD50XHD2DW6
pmid: 18480006
|
|
|
[17] |
Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clinical Cancer Research, 2014, 20(24):6418-6428.
doi: 10.1158/1078-0432.CCR-14-1170
pmid: 25320357
|
|
|
[18] |
Liu Y, Li P K, Li C L, et al. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. Journal of Biological Chemistry, 2010, 285(35): 27429-27439.
doi: 10.1074/jbc.M110.142752
pmid: 20562100
|
|
|
[19] |
Went P T H, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Human Pathology, 2004, 35(1): 122-128.
doi: 10.1016/j.humpath.2003.08.026
pmid: 14745734
|
|
|
[20] |
Deng Z L, Wu Y H, Ma W B, et al. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunology, 2015, 16(1): 1-9.
doi: 10.1186/s12865-014-0064-x
|
|
|
[21] |
Zhang B L, Li D, Gong Y L, et al. Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum Gene Ther, 2019, 30(4):402-412.
doi: 10.1089/hum.2018.229
|
|
|
[22] |
Yan T, Zhu L F, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Experimental Hematology & Oncology, 2023, 12(1): 1-18.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|